Furosemide‐induced genotoxicity and cytotoxicity in the hepatocytes, but weak genotoxicity in the bone marrow cells of mice
Authors:
- Durga Nand TripathiDTDurga Nand Tripathi
- Gopabandhu B. JenaGJGopabandhu B. Jena
- 24 February 2011
- journal article
- research article
- Published by Wiley in Fundamental & Clinical Pharmacology
- Vol. 26 (3) , 383-392
Abstract
Furosemide (FS) is a potent loop diuretic widely used in the management of fluid retention associated with cardiac, renal, and hepatic failure as well as for the treatment of hypertension. FS is a well‐characterized and known hepatotoxin in both human and animal test systems. In this study, an attempt has been made to investigate the in vivo genotoxicity of FS at the hepatotoxic equivalent doses using the chromosomal aberration and the comet assay in the bone marrow cells of mice as the endpoints of evaluation. The animals were treated with FS at the doses of 2.5, 5, 10, 20, 40, and 80 mg/kg/body weight (bw) intraperitoneal (ip) for both single (24 h) and repeated dose (seven consecutive days) toxicity studies. FS toxicity in the hepatocytes was evaluated using the parameters, such as, alanine‐/aspartate‐aminotransferase (ALT/AST), single cell gel electrophoresis (comet), tissue histology, DNA fragmentation, and TUNEL assay as the endpoints. The results clearly demonstrate that FS produced toxic responses in the hepatocytes as evident from increased ALT/AST level, DNA damage, TUNEL positive cells and increased DNA fragmentation in mice in vivo. However, it is interesting that in bone marrow cells, FS did not induced structural chromosomal abberations, but produced mild DNA strand breaks as observed by the comet assay. So it is considered as weak genotoxic toward the bone marrow cells when compared to the hepatocytes of mice.Keywords
This publication has 36 references indexed in Scilit:
- Intervention of astaxanthin against cyclophosphamide-induced oxidative stress and DNA damage: A study in miceChemico-Biological Interactions, 2009
- Update on genotoxicity and carcinogenicity testing of 472 marketed pharmaceuticalsMutation Research - Reviews in Mutation Research, 2009
- Investigation of the effect of a panel of model hepatotoxins on the Nrf2-Keap1 defence response pathway in CD-1 miceToxicology, 2008
- Formation of cytotoxic protein reactive metabolites from furosemide: Biological consequences of drug metabolismToxicology, 2007
- Immunosuppressive and cytotoxic effects of furosemide on human peripheral blood mononuclear cellsAnnals of Allergy, Asthma & Immunology, 1999
- Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation.Journal of Cell Biology, 1992
- Ototoxicity of furosemide during developmentThe Laryngoscope, 1991
- Toxicology and carcinogenicity studies of diuretics in F344 rats and B6C3F1 mice 2. FurosemideJournal of Applied Toxicology, 1990
- Furosemide induced hepatotoxicityThe Journal of Pathology, 1981
- The role of biliary excretion in the hepatotoxicity of furosemide in the mouseToxicology and Applied Pharmacology, 1977